

IN THE CLAIMS

Please amend claims 38 and 39 as follows:

1. – 30. (CANCELED)

31. (PREVIOUSLY PRESENTED) A synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and which comprises a nucleotide sequence selected from the group consisting of TGACGTCA and SEQ ID NOS: 1-4, 6-12, 14-15, 18-101, 103, 105, 107 and 109, wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

32. (CANCELED)

33. (CANCELED)

34. (WITHDRAWN) A synthetic oligonucleotide comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, and 16-110.

35. (CANCELED)

36. (WITHDRAWN) The synthetic oligonucleotide of claim 34, wherein the oligonucleotide is 15 to 70 nucleotides in length.

37. (WITHDRAWN) The synthetic oligonucleotide of claim 34, wherein the oligonucleotide is 15 to 50 nucleotides in length, and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, 13, 18-101, 103, 105, 107 and 109.

BEST AVAILABLE COPY

BEST AVAILABLE COPY

BEST AVAILABLE COPY

38. (WITHDRAWN) The synthetic oligonucleotide of claim 34, wherein the oligonucleotide is 20 to 30 nucleotides in length, and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, ~~13~~, 18-101, 103, 105, 107 and 109.

39. (WITHDRAWN) The synthetic oligonucleotide of claim 34, wherein the oligonucleotide is 30 nucleotides in length, and wherein the nucleotide sequence is selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, ~~13~~, 18-101, 103, 105, 107 and 109.

40. (WITHDRAWN) The synthetic oligonucleotide of claim 34, which comprises a phosphorothioate, deoxyribonucleic guanidine (DNG), or ribonucleic guanidine (RNG) oligonucleotide.

41. (WITHDRAWN) A synthetic oligonucleotide comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the nucleotide sequence of the synthetic oligonucleotide is a sequence selected from the group consisting of SEQ ID NOS: 1, 2, 4, 6-8, and 13-110.

42. (WITHDRAWN) The synthetic oligonucleotide of claim 41, which comprises a phosphorothioate, deoxyribonucleic guanidine (DNG), or ribonucleic guanidine (RNG) oligonucleotide.

43. (WITHDRAWN) A pharmaceutically acceptable salt of a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide.

44. (WITHDRAWN) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 34.

45. (WITHDRAWN) A pharmaceutically acceptable salt of the synthetic oligonucleotide of claim 41.

BEST AVAILABLE COPY

46. (PREVIOUSLY PRESENTED) A composition comprising a synthetic oligonucleotide of at least 26 nucleotides in length and comprising a 5mCpG dinucleotide, wherein the 5mC is a C-5 methylcytosine, and wherein the synthetic oligonucleotide comprises a phosphorothioate nucleotide, and a pharmaceutically acceptable carrier.

47. (WITHDRAWN) A composition comprising the synthetic oligonucleotide of claim 34 and a pharmaceutically acceptable carrier.

48. (WITHDRAWN) A composition comprising the synthetic oligonucleotide of claim 41 and a pharmaceutically acceptable carrier.

49. (WITHDRAWN) The synthetic oligonucleotide of claim 34, which is modified to include a peptide nucleic acid (PNA).

50. (WITHDRAWN) The synthetic oligonucleotide of claim 41, which is modified to include a peptide nucleic acid (PNA).

BEST AVAILABLE COPY